GlassScriptPhysician profile
Daphna Henkin
NPI 1831160233
$3,651.65
in general payments reported to CMS, 2019-2025
35 companies · $608 in 2025
The $608 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $242 · 2021: $601 · 2022: $659 · 2023: $392 · 2024: $664 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,663.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $365.80 | 2021-2025 | |
| Novo Nordisk INC | $324.72 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $299.09 | 2019-2025 | Veozah |
| Pfizer INC. | $286.65 | 2020-2025 | |
| Amgen INC. | $263.74 | 2021-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $221.30 | 2019-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $144.82 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $143.27 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $142.59 | 2021-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $140.79 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Sanofi-Aventis U.S. LLC | $136.66 | 2019-2022 | |
| Gilead Sciences, INC. | $131.00 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $130.26 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.45 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.09 | 2020-2025 | Xifaxan |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $83.63 | 2023-2024 | Cologuard Collection Kit |
| Amneal Pharmaceuticals LLC | $76.79 | 2019-2023 | Unithroid |
| Radius Health, INC. | $71.13 | 2019-2024 | Tymlos |
| Daiichi Sankyo INC. | $56.29 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.52 | 2021-2022 | |
| Ortho-Clinical Diagnostics, INC. | $39.49 | 2025 | Vitros |
| Allergan, INC. | $36.57 | 2019-2020 | |
| Amarin Pharma, INC. | $31.35 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.11 | 2022 | |
| Horizon Therapeutics Plc | $28.95 | 2021 | |
| Eisai INC. | $26.11 | 2020-2021 | |
| Bausch Health US, LLC | $21.79 | 2025 | Aplenzin |
| Myriad Women'S Health, INC. | $21.52 | 2023 | Myrisk |
| Quidel Corporation | $19.87 | 2021 | |
| Dexcom, INC. | $19.01 | 2022 | |
| Ibsa Pharma INC. | $14.66 | 2022 | |
| Sanofi Pasteur INC. | $14.41 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.96 | 2020 | |
| Ironwood Pharmaceuticals, INC | $11.34 | 2020 | |
| Arbor Pharmaceuticals, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daphna Henkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.